BioSyent Yönetim

Yönetim kriter kontrolleri 3/4

BioSyent CEO'su René Goehrum, May1999 tarihinde atandı, in görev süresi 25.5 yıldır. in toplam yıllık tazminatı CA$ 747.51K olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.7% maaş ve 52.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 8.61% ine doğrudan sahiptir ve bu hisseler CA$ 11.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.2 yıl ve 8.8 yıldır.

Anahtar bilgiler

René Goehrum

İcra Kurulu Başkanı

CA$747.5k

Toplam tazminat

CEO maaş yüzdesi	47.7%
CEO görev süresi	25.5yrs
CEO sahipliği	8.6%
Yönetim ortalama görev süresi	6.2yrs
Yönetim Kurulu ortalama görev süresi	8.8yrs

Son yönetim güncellemeleri

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

Recent updates

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

CEO Tazminat Analizi

René Goehrum'un ücretlendirmesi BioSyent'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	CA$7m
Jun 30 2024	n/a	n/a	CA$7m
Mar 31 2024	n/a	n/a	CA$7m
Dec 31 2023	CA$748k	CA$357k	CA$6m
Sep 30 2023	n/a	n/a	CA$6m
Jun 30 2023	n/a	n/a	CA$5m
Mar 31 2023	n/a	n/a	CA$5m
Dec 31 2022	CA$681k	CA$343k	CA$5m
Sep 30 2022	n/a	n/a	CA$6m
Jun 30 2022	n/a	n/a	CA$6m
Mar 31 2022	n/a	n/a	CA$6m
Dec 31 2021	CA$681k	CA$329k	CA$6m
Sep 30 2021	n/a	n/a	CA$5m
Jun 30 2021	n/a	n/a	CA$4m
Mar 31 2021	n/a	n/a	CA$4m
Dec 31 2020	CA$649k	CA$325k	CA$4m
Sep 30 2020	n/a	n/a	CA$4m
Jun 30 2020	n/a	n/a	CA$5m
Mar 31 2020	n/a	n/a	CA$5m
Dec 31 2019	CA$497k	CA$310k	CA$4m
Sep 30 2019	n/a	n/a	CA$5m
Jun 30 2019	n/a	n/a	CA$5m
Mar 31 2019	n/a	n/a	CA$6m
Dec 31 2018	CA$528k	CA$300k	CA$6m
Sep 30 2018	n/a	n/a	CA$5m
Jun 30 2018	n/a	n/a	CA$6m
Mar 31 2018	n/a	n/a	CA$5m
Dec 31 2017	CA$509k	CA$280k	CA$5m

Tazminat ve Piyasa: René 'nin toplam tazminatı ($USD 535.40K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 169.37K ).

Tazminat ve Kazançlar: René 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

René Goehrum (65 yo)

25.5yrs

Görev süresi

CA$747,509

Tazminat

Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
René Goehrum	Chairman	25.5yrs	CA$747.51k	8.61% CA$ 11.3m
Robert March	VP of Finance & CFO	6.2yrs	CA$340.38k	0.49% CA$ 635.7k
Joost van der Mark	Vice President of Corporate Development	6.2yrs	CA$315.75k	0.45% CA$ 595.8k
Neelu Atwal	Director of Human Resources	5.8yrs	Veri yok	0.17% CA$ 228.0k

6.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: RX 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
René Goehrum	Chairman	28.8yrs	CA$747.51k	8.61% CA$ 11.3m
Joseph Arcuri	Independent Director	6.5yrs	CA$43.04k	0.097% CA$ 127.4k
Larry Andrews	Independent Director	6.8yrs	CA$39.98k	0.084% CA$ 109.4k
Peter Lockhard	Lead Independent Director	22.4yrs	CA$42.25k	1.55% CA$ 2.0m
Sara Elford	Independent Director	6.8yrs	CA$39.00k	0.13% CA$ 171.2k
Stephen Wilton	Independent Director	10.8yrs	CA$39.00k	0.022% CA$ 29.4k

8.8yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

BioSyent Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold CA$55k worth of stock

BioSyent Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

Insufficient new directors

BioSyent Inc., Annual General Meeting, May 26, 2021

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024

BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Second quarter dividend of CA$0.045 announced

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024

Insider recently sold CA$55k worth of stock

First quarter dividend of CA$0.045 announced

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024

BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent Inc., Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024

Upcoming dividend of CA$0.045 per share

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Third quarter dividend increased to CA$0.045

BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024

Upcoming dividend of CA$0.04 per share at 1.9% yield

Price target increased by 13% to CA$9.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023

BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023

BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023

BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Inaugural dividend of CA$0.04 per share

BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CA$10.00

Insufficient new directors

BioSyent Inc. to Report Q3, 2022 Results on Nov 16, 2022

Now 21% undervalued after recent price drop

BioSyent Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Announces Adoption of Dividend Policy

BioSyent Inc. to Report Q2, 2022 Results on Aug 23, 2022

BioSyent Inc. to Report Q1, 2022 Results on May 18, 2022

Price target increased to CA$10.00

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. to Report Q4, 2021 Results on Mar 09, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CA$0.14 (vs CA$0.075 in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.08 (vs CA$0.056 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.11 in 1Q 2020)

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc., Annual General Meeting, May 26, 2021

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2020 earnings released: EPS CA$0.29 (vs CA$0.31 in FY 2019)

Biosyent Inc. Announces Combogesic Availability in Many Pharmacies Across Canada

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent Inc. to Report Q4, 2020 Results on Mar 17, 2021

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$8.19

Investor sentiment improved over the past week

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Revenue and earnings miss expectations

BioSyent Inc. to Report Q3, 2020 Results on Nov 26, 2020